SEARCH

SEARCH BY CITATION

References

  • 1
    Bennett D,Burton A,Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1: Assessment. Pharm Ther. 2005; 30: 296-301.
  • 2
    Caraceni A,Martini C,Zecca E, et al;Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004; 18: 177-183.
  • 3
    Portenoy RK,Payne D,Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999; 81: 129-134.
  • 4
    Miaskowski C,Cleary J,Burney R, et al. Guideline for the management of cancer pain in adults and children. APS Clinical Practice Guidelines Series, No. 3. Glenview, IL: American Pain Society; 2005.
  • 5
    Zeppetella G,Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006;( 1): CD004311.
  • 6
    Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med. 1996; 335: 1124-1132.
  • 7
    Bennett D,Burton AW,Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: Management. Pharm Ther. 2005; 30: 354-361.
  • 8
    Portenoy RK,Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990; 41: 273-281.
  • 9
    Zeppetella G,O'Doherty CA,Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000; 20: 87-92.
  • 10
    Mercadante S,Radbruch L,Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002; 94: 832-839.
  • 11
    Hwang SS,Chang VT,Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003; 101: 55-64.
  • 12
    Durfee S,Messina J,Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv. 2006; 4: 1-5.
  • 13
    Portenoy RK,Taylor D,Messina J,Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006; 22: 805-811.
  • 14
    Slatkin NE,Xie F,Messina J,Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain: a double-blind, randomized, placebo-controlled study. J Support Oncol. 2007; 5: 327-334.
  • 15
    International Conference on Harmonisation Expert Working Group. ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). 1996. Available at: http://www.ich.org/LOB/media/MEDIA482.pdf. Accessed on March 30, 2009.
  • 16
    Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth. 1998; 81: 58-68.